NO20080951L - Farmasoytisk blanding for behandling av kardiovaskulaere lidelser - Google Patents

Farmasoytisk blanding for behandling av kardiovaskulaere lidelser

Info

Publication number
NO20080951L
NO20080951L NO20080951A NO20080951A NO20080951L NO 20080951 L NO20080951 L NO 20080951L NO 20080951 A NO20080951 A NO 20080951A NO 20080951 A NO20080951 A NO 20080951A NO 20080951 L NO20080951 L NO 20080951L
Authority
NO
Norway
Prior art keywords
immunotherapy
treatment
pharmaceutical composition
cardiovascular disorders
oxidized ldl
Prior art date
Application number
NO20080951A
Other languages
English (en)
Inventor
Roland Carlsson
Jan Nilsson
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of NO20080951L publication Critical patent/NO20080951L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anvendelse av immunterapi mot oksidert LDL for å indusere regresjon av allerede eksisterende ateroskleroselesjoner i et individ. Immunterapien kan være passiv immunterapi ved bruk av antistoffer som bindes til epitoper til stede på oksidert LDL, eller aktiv immunterapi ved bruk av en vaksineblanding for induksjon av en immunrespons mot epitoper til stede på oksidert LDL.
NO20080951A 2005-09-02 2008-02-25 Farmasoytisk blanding for behandling av kardiovaskulaere lidelser NO20080951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517878.5A GB0517878D0 (en) 2005-09-02 2005-09-02 Immunotherapeutic treatment
PCT/EP2006/008594 WO2007025781A2 (en) 2005-09-02 2006-09-04 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques

Publications (1)

Publication Number Publication Date
NO20080951L true NO20080951L (no) 2008-06-02

Family

ID=35220745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080951A NO20080951L (no) 2005-09-02 2008-02-25 Farmasoytisk blanding for behandling av kardiovaskulaere lidelser

Country Status (16)

Country Link
US (1) US20090208503A1 (no)
EP (2) EP1928913B1 (no)
JP (1) JP2009506995A (no)
KR (2) KR20120101074A (no)
CN (1) CN101316863A (no)
AU (1) AU2006286729A1 (no)
BR (1) BRPI0615313A2 (no)
CA (1) CA2621017A1 (no)
GB (1) GB0517878D0 (no)
IL (1) IL189847A (no)
NO (1) NO20080951L (no)
NZ (1) NZ566237A (no)
RU (1) RU2454428C2 (no)
UA (1) UA96275C2 (no)
WO (1) WO2007025781A2 (no)
ZA (1) ZA200801959B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
UA100255C2 (uk) * 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
CA2817543A1 (en) * 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2592423A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US12473342B2 (en) 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
WO2019215300A1 (en) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Antibodies for use in combination therapy
US11690912B2 (en) 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
EP4058042A4 (en) * 2019-11-12 2023-12-27 Abcentra, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2025151504A1 (en) * 2024-01-08 2025-07-17 Abcentra, Llc Compositions and methods for reducing risk of major adverse cardiovascular event

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20030157567A1 (en) * 1999-09-20 2003-08-21 Joe Lunec Oxidised fragments of apolipoprotein B and their use
US6716410B1 (en) * 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
DE10059930A1 (de) * 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE10123074A1 (de) 2001-05-10 2002-11-14 Monforts Textilmaschinen Gmbh Vorrichtung zur Wärmebehandlung einer Warenbahn
CA2500895A1 (en) 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis

Also Published As

Publication number Publication date
ZA200801959B (en) 2009-08-26
AU2006286729A1 (en) 2007-03-08
NZ566237A (en) 2011-07-29
KR20120101074A (ko) 2012-09-12
CA2621017A1 (en) 2007-03-08
EP2319868A1 (en) 2011-05-11
US20090208503A1 (en) 2009-08-20
IL189847A (en) 2012-02-29
WO2007025781A3 (en) 2007-05-03
BRPI0615313A2 (pt) 2012-12-04
WO2007025781A2 (en) 2007-03-08
JP2009506995A (ja) 2009-02-19
EP1928913A2 (en) 2008-06-11
EP1928913B1 (en) 2013-06-26
RU2008112664A (ru) 2009-10-10
RU2454428C2 (ru) 2012-06-27
KR20080053483A (ko) 2008-06-13
IL189847A0 (en) 2008-11-03
CN101316863A (zh) 2008-12-03
UA96275C2 (ru) 2011-10-25
GB0517878D0 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
NO20080951L (no) Farmasoytisk blanding for behandling av kardiovaskulaere lidelser
CL2016001254A1 (es) Mólecula unión cd3 capaz de unirse a cd3 humanos y no humanos (divisional de sol. 3329-13).
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
PE20140825A1 (es) Anticuerpos contra il-6 y sus usos
NO20071090L (no) Behandling av pulmonal hypertensjon ved inhalert iloprost med en mikropartikkelformulering.
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
AR083747A1 (es) Anticuerpos anti-il-23
AU2010217100A8 (en) Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
SMT201100058B (it) Produzione di squalene a partire da lieviti iperproduttivi
JP2007520566A5 (no)
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
JP2013540292A5 (no)
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
CN110198739A (zh) 一种pd-l1抗体药物组合物及其用途
NO20065252L (no) Behandling av forstyrrelser
EA201270124A1 (ru) Новые терапевтические и диагностические средства
NO20061412L (no) Terapi av okulaere foretyrrelser
WO2014165028A8 (en) Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application